| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiopancreatography, Endoscopic Retrograde | 35 | 2016 | 348 | 4.530 |
Why?
|
| Pancreatitis, Chronic | 24 | 2022 | 168 | 3.470 |
Why?
|
| Endosonography | 17 | 2012 | 177 | 3.410 |
Why?
|
| Pancreatitis | 24 | 2016 | 279 | 3.340 |
Why?
|
| Sphincter of Oddi Dysfunction | 10 | 2015 | 48 | 2.080 |
Why?
|
| Endoscopy, Gastrointestinal | 12 | 2016 | 170 | 1.800 |
Why?
|
| Pancreatic Neoplasms | 10 | 2014 | 332 | 1.730 |
Why?
|
| Cholestasis | 7 | 2016 | 90 | 1.640 |
Why?
|
| Colonoscopy | 7 | 2013 | 156 | 1.480 |
Why?
|
| Sphincterotomy, Endoscopic | 10 | 2015 | 79 | 1.460 |
Why?
|
| Adenocarcinoma | 6 | 2015 | 475 | 1.380 |
Why?
|
| Pancreas | 12 | 2016 | 225 | 1.370 |
Why?
|
| Abdominal Pain | 10 | 2022 | 97 | 1.220 |
Why?
|
| Gastrointestinal Hemorrhage | 6 | 2015 | 185 | 1.150 |
Why?
|
| Endoscopy | 6 | 2014 | 464 | 1.040 |
Why?
|
| Pancreatic Ducts | 8 | 2016 | 76 | 1.020 |
Why?
|
| Colonic Polyps | 5 | 2013 | 63 | 1.010 |
Why?
|
| Humans | 124 | 2022 | 68525 | 1.000 |
Why?
|
| Endoscopy, Digestive System | 5 | 2013 | 78 | 0.980 |
Why?
|
| Gallstones | 5 | 2013 | 58 | 0.960 |
Why?
|
| Middle Aged | 66 | 2021 | 21119 | 0.900 |
Why?
|
| Stents | 11 | 2016 | 657 | 0.900 |
Why?
|
| Colorectal Neoplasms | 4 | 2010 | 560 | 0.890 |
Why?
|
| Aged | 49 | 2021 | 14842 | 0.800 |
Why?
|
| Male | 75 | 2021 | 37281 | 0.790 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2014 | 503 | 0.790 |
Why?
|
| Female | 73 | 2021 | 38015 | 0.750 |
Why?
|
| Risk Assessment | 9 | 2016 | 2004 | 0.730 |
Why?
|
| Quality Improvement | 2 | 2014 | 413 | 0.710 |
Why?
|
| Adult | 53 | 2021 | 21375 | 0.710 |
Why?
|
| Pain | 6 | 2021 | 472 | 0.710 |
Why?
|
| Risk Factors | 26 | 2019 | 5719 | 0.690 |
Why?
|
| Contrast Media | 2 | 2012 | 594 | 0.640 |
Why?
|
| Credentialing | 5 | 2008 | 23 | 0.640 |
Why?
|
| Cohort Studies | 14 | 2021 | 2356 | 0.640 |
Why?
|
| Biopsy, Fine-Needle | 6 | 2014 | 76 | 0.630 |
Why?
|
| Jaundice, Obstructive | 2 | 2014 | 8 | 0.620 |
Why?
|
| Predictive Value of Tests | 13 | 2014 | 1465 | 0.620 |
Why?
|
| Surgical Wound Infection | 2 | 2010 | 168 | 0.610 |
Why?
|
| Pancreatic Diseases | 6 | 2022 | 66 | 0.600 |
Why?
|
| Research Design | 5 | 2016 | 729 | 0.570 |
Why?
|
| Cost-Benefit Analysis | 7 | 2014 | 503 | 0.570 |
Why?
|
| Laparoscopy | 3 | 2010 | 237 | 0.570 |
Why?
|
| Intestine, Small | 2 | 2015 | 89 | 0.560 |
Why?
|
| Double-Balloon Enteroscopy | 1 | 2015 | 4 | 0.550 |
Why?
|
| Angiodysplasia | 1 | 2015 | 4 | 0.550 |
Why?
|
| Postoperative Hemorrhage | 1 | 2015 | 69 | 0.530 |
Why?
|
| Endoscopes, Gastrointestinal | 3 | 2011 | 17 | 0.530 |
Why?
|
| Mass Screening | 3 | 2010 | 837 | 0.530 |
Why?
|
| Recurrence | 10 | 2015 | 948 | 0.520 |
Why?
|
| Bile Ducts | 2 | 2013 | 59 | 0.500 |
Why?
|
| Peptic Ulcer Hemorrhage | 3 | 2013 | 26 | 0.500 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2014 | 16 | 0.500 |
Why?
|
| Sensitivity and Specificity | 12 | 2015 | 1753 | 0.490 |
Why?
|
| Treatment Outcome | 25 | 2016 | 7028 | 0.490 |
Why?
|
| Surveys and Questionnaires | 9 | 2019 | 2798 | 0.490 |
Why?
|
| Gastroenterology | 4 | 2016 | 98 | 0.490 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 4 | 2013 | 20 | 0.480 |
Why?
|
| Omeprazole | 2 | 2005 | 53 | 0.480 |
Why?
|
| Indomethacin | 4 | 2016 | 107 | 0.470 |
Why?
|
| Aged, 80 and over | 15 | 2015 | 4843 | 0.470 |
Why?
|
| Retrospective Studies | 23 | 2020 | 7264 | 0.470 |
Why?
|
| Cost Savings | 1 | 2014 | 110 | 0.460 |
Why?
|
| Prospective Studies | 16 | 2020 | 3702 | 0.460 |
Why?
|
| Tissue Adhesions | 2 | 2010 | 21 | 0.450 |
Why?
|
| Choledochostomy | 2 | 2015 | 10 | 0.450 |
Why?
|
| Upper Gastrointestinal Tract | 2 | 2010 | 9 | 0.450 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2016 | 239 | 0.440 |
Why?
|
| Esophageal Neoplasms | 3 | 2015 | 150 | 0.440 |
Why?
|
| Catheterization | 1 | 2013 | 209 | 0.440 |
Why?
|
| Prosthesis Design | 1 | 2014 | 301 | 0.440 |
Why?
|
| Hepatitis C, Chronic | 2 | 2005 | 86 | 0.430 |
Why?
|
| Health Care Costs | 2 | 2005 | 346 | 0.420 |
Why?
|
| Suture Techniques | 2 | 2010 | 75 | 0.420 |
Why?
|
| Postoperative Complications | 7 | 2016 | 1615 | 0.420 |
Why?
|
| Colon | 2 | 2010 | 168 | 0.420 |
Why?
|
| Duodenal Neoplasms | 1 | 2011 | 9 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2015 | 929 | 0.400 |
Why?
|
| Multivariate Analysis | 8 | 2014 | 1046 | 0.400 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 1851 | 0.390 |
Why?
|
| Cholecystectomy | 4 | 2014 | 79 | 0.380 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2010 | 7 | 0.380 |
Why?
|
| Antioxidants | 2 | 2010 | 304 | 0.380 |
Why?
|
| Time and Motion Studies | 1 | 2010 | 16 | 0.370 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 46 | 0.370 |
Why?
|
| Image Enhancement | 1 | 2011 | 143 | 0.360 |
Why?
|
| Fluorocarbons | 1 | 2011 | 82 | 0.360 |
Why?
|
| Peritonitis | 1 | 2010 | 46 | 0.360 |
Why?
|
| Stomach Neoplasms | 1 | 2010 | 64 | 0.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2010 | 46 | 0.360 |
Why?
|
| Biliary Tract Diseases | 3 | 2013 | 50 | 0.350 |
Why?
|
| Proton Pump Inhibitors | 4 | 2012 | 91 | 0.350 |
Why?
|
| Lung Diseases | 1 | 2011 | 175 | 0.350 |
Why?
|
| Quality Assurance, Health Care | 2 | 2013 | 177 | 0.350 |
Why?
|
| Endoscopes | 1 | 2009 | 36 | 0.340 |
Why?
|
| Adenoma | 1 | 2010 | 132 | 0.340 |
Why?
|
| Patient Dropouts | 1 | 2009 | 98 | 0.330 |
Why?
|
| Bacterial Infections | 1 | 2010 | 163 | 0.330 |
Why?
|
| Allopurinol | 1 | 2008 | 36 | 0.320 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2008 | 23 | 0.320 |
Why?
|
| Manometry | 5 | 2015 | 276 | 0.310 |
Why?
|
| Sex Factors | 6 | 2017 | 1265 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 444 | 0.310 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2007 | 62 | 0.310 |
Why?
|
| Free Radical Scavengers | 1 | 2008 | 112 | 0.300 |
Why?
|
| Follow-Up Studies | 12 | 2015 | 3256 | 0.300 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 848 | 0.300 |
Why?
|
| Quality of Life | 7 | 2020 | 1515 | 0.290 |
Why?
|
| Radiology | 1 | 2008 | 97 | 0.290 |
Why?
|
| Length of Stay | 5 | 2013 | 780 | 0.290 |
Why?
|
| Gastric Bypass | 3 | 2015 | 83 | 0.290 |
Why?
|
| Needles | 1 | 2006 | 34 | 0.290 |
Why?
|
| Health Status Indicators | 1 | 2007 | 117 | 0.280 |
Why?
|
| Smoking | 5 | 2019 | 1449 | 0.280 |
Why?
|
| Fundoplication | 2 | 2004 | 27 | 0.280 |
Why?
|
| Sulfoxides | 1 | 2005 | 16 | 0.280 |
Why?
|
| Odds Ratio | 5 | 2014 | 880 | 0.280 |
Why?
|
| Common Bile Duct Diseases | 2 | 2016 | 24 | 0.280 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 2077 | 0.280 |
Why?
|
| Anti-Ulcer Agents | 1 | 2005 | 47 | 0.270 |
Why?
|
| Young Adult | 12 | 2020 | 5708 | 0.270 |
Why?
|
| Admitting Department, Hospital | 1 | 2005 | 1 | 0.270 |
Why?
|
| Alanine Transaminase | 1 | 2005 | 137 | 0.260 |
Why?
|
| Sphincter of Oddi | 2 | 2015 | 51 | 0.260 |
Why?
|
| Utilization Review | 1 | 2005 | 48 | 0.260 |
Why?
|
| Critical Pathways | 1 | 2005 | 33 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2015 | 2222 | 0.260 |
Why?
|
| Incidence | 7 | 2015 | 1582 | 0.260 |
Why?
|
| Pancreatitis, Alcoholic | 2 | 2016 | 11 | 0.260 |
Why?
|
| Physical Examination | 1 | 2005 | 152 | 0.260 |
Why?
|
| Hematocrit | 1 | 2004 | 70 | 0.260 |
Why?
|
| Benzimidazoles | 1 | 2005 | 128 | 0.250 |
Why?
|
| Acute Disease | 5 | 2022 | 658 | 0.250 |
Why?
|
| Carcinoma, Verrucous | 1 | 2004 | 5 | 0.250 |
Why?
|
| Liver Cirrhosis | 2 | 2005 | 301 | 0.250 |
Why?
|
| Plastics | 3 | 2016 | 25 | 0.250 |
Why?
|
| Alcohol Drinking | 4 | 2019 | 805 | 0.250 |
Why?
|
| Neoplasm, Residual | 1 | 2004 | 33 | 0.250 |
Why?
|
| Second-Look Surgery | 1 | 2004 | 5 | 0.250 |
Why?
|
| Liver | 2 | 2001 | 1118 | 0.250 |
Why?
|
| Societies, Medical | 5 | 2016 | 403 | 0.250 |
Why?
|
| Medication Errors | 1 | 2005 | 116 | 0.250 |
Why?
|
| Genetic Loci | 2 | 2021 | 59 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 4 | 2013 | 772 | 0.250 |
Why?
|
| Guideline Adherence | 3 | 2013 | 284 | 0.240 |
Why?
|
| Brachytherapy | 1 | 2004 | 79 | 0.240 |
Why?
|
| Rectal Neoplasms | 1 | 2004 | 75 | 0.240 |
Why?
|
| Cholangiography | 1 | 2003 | 55 | 0.240 |
Why?
|
| United States | 13 | 2017 | 7335 | 0.230 |
Why?
|
| Cross-Sectional Studies | 7 | 2020 | 2264 | 0.230 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 938 | 0.230 |
Why?
|
| Clinical Competence | 6 | 2008 | 657 | 0.230 |
Why?
|
| Canada | 7 | 2011 | 266 | 0.230 |
Why?
|
| Pilot Projects | 8 | 2013 | 1341 | 0.220 |
Why?
|
| Patient Discharge | 1 | 2005 | 294 | 0.220 |
Why?
|
| Benchmarking | 2 | 2013 | 91 | 0.220 |
Why?
|
| Esophagitis, Peptic | 1 | 2002 | 33 | 0.220 |
Why?
|
| Breath Tests | 1 | 2002 | 23 | 0.220 |
Why?
|
| Observer Variation | 4 | 2011 | 330 | 0.210 |
Why?
|
| Gastroesophageal Reflux | 1 | 2004 | 318 | 0.210 |
Why?
|
| Prognosis | 5 | 2015 | 2093 | 0.210 |
Why?
|
| Adolescent | 11 | 2019 | 8903 | 0.200 |
Why?
|
| ROC Curve | 4 | 2007 | 392 | 0.200 |
Why?
|
| Hyperhomocysteinemia | 1 | 2001 | 15 | 0.200 |
Why?
|
| Logistic Models | 5 | 2015 | 1419 | 0.200 |
Why?
|
| Terminology as Topic | 2 | 2014 | 141 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2014 | 621 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2323 | 0.190 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2001 | 59 | 0.190 |
Why?
|
| Prevalence | 4 | 2016 | 1609 | 0.190 |
Why?
|
| Pancreatectomy | 2 | 2013 | 129 | 0.190 |
Why?
|
| Hemostasis, Endoscopic | 2 | 2012 | 17 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 1026 | 0.190 |
Why?
|
| Physicians | 2 | 2019 | 324 | 0.190 |
Why?
|
| Aspergillosis | 1 | 2000 | 20 | 0.190 |
Why?
|
| Time Factors | 8 | 2016 | 4655 | 0.190 |
Why?
|
| Demography | 2 | 2019 | 279 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 766 | 0.180 |
Why?
|
| Biopsy | 3 | 2010 | 539 | 0.180 |
Why?
|
| Confidence Intervals | 3 | 2010 | 242 | 0.180 |
Why?
|
| Selection Bias | 2 | 2009 | 23 | 0.180 |
Why?
|
| Cholelithiasis | 2 | 2013 | 66 | 0.180 |
Why?
|
| Cross Infection | 2 | 2011 | 195 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 659 | 0.170 |
Why?
|
| Tobacco Smoking | 1 | 2019 | 41 | 0.170 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 1998 | 9 | 0.170 |
Why?
|
| Azathioprine | 1 | 1998 | 16 | 0.170 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 216 | 0.170 |
Why?
|
| Emergency Service, Hospital | 1 | 2005 | 711 | 0.170 |
Why?
|
| Survival Rate | 2 | 2014 | 1055 | 0.170 |
Why?
|
| Analgesics, Opioid | 3 | 2014 | 498 | 0.160 |
Why?
|
| Drug Hypersensitivity | 1 | 1998 | 35 | 0.160 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 426 | 0.160 |
Why?
|
| Crohn Disease | 1 | 1998 | 38 | 0.160 |
Why?
|
| Metals | 2 | 2014 | 100 | 0.160 |
Why?
|
| Microspheres | 2 | 2011 | 59 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2010 | 652 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2000 | 163 | 0.160 |
Why?
|
| Trypsin | 2 | 2020 | 64 | 0.160 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2008 | 47 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2015 | 624 | 0.150 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 319 | 0.150 |
Why?
|
| Obesity, Morbid | 2 | 2011 | 172 | 0.150 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2016 | 6 | 0.150 |
Why?
|
| Liver Transplantation | 1 | 2000 | 400 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 627 | 0.140 |
Why?
|
| Research Support as Topic | 1 | 2016 | 58 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2020 | 438 | 0.140 |
Why?
|
| Pain Measurement | 3 | 2016 | 328 | 0.140 |
Why?
|
| Self Concept | 1 | 2016 | 132 | 0.140 |
Why?
|
| Digestive System Diseases | 1 | 2015 | 16 | 0.130 |
Why?
|
| Decision Trees | 2 | 2005 | 74 | 0.130 |
Why?
|
| Age Factors | 3 | 2017 | 1860 | 0.130 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 88 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2015 | 26 | 0.130 |
Why?
|
| Equipment Reuse | 2 | 2011 | 7 | 0.130 |
Why?
|
| Bicarbonates | 1 | 2014 | 21 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 1998 | 514 | 0.130 |
Why?
|
| Cell Membrane Permeability | 1 | 2014 | 59 | 0.120 |
Why?
|
| Cell Biology | 1 | 2014 | 4 | 0.120 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2014 | 30 | 0.120 |
Why?
|
| Administration, Rectal | 4 | 2016 | 26 | 0.120 |
Why?
|
| Colectomy | 2 | 2015 | 64 | 0.120 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2014 | 51 | 0.120 |
Why?
|
| Biliary Tract | 1 | 2014 | 17 | 0.120 |
Why?
|
| Pain Management | 2 | 2013 | 186 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 30 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 54 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 39 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 1139 | 0.120 |
Why?
|
| North America | 3 | 2020 | 111 | 0.120 |
Why?
|
| Health Status | 2 | 2014 | 429 | 0.120 |
Why?
|
| Calcinosis | 2 | 2016 | 241 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2014 | 238 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2014 | 130 | 0.110 |
Why?
|
| Trypsinogen | 1 | 2012 | 7 | 0.110 |
Why?
|
| Claudins | 1 | 2012 | 6 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 508 | 0.110 |
Why?
|
| Mental Recall | 1 | 2013 | 72 | 0.110 |
Why?
|
| Health Services | 1 | 2013 | 87 | 0.110 |
Why?
|
| Sphincterotomy, Transduodenal | 2 | 2013 | 24 | 0.110 |
Why?
|
| Proteomics | 1 | 2015 | 246 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2016 | 310 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 536 | 0.110 |
Why?
|
| Disability Evaluation | 2 | 2014 | 298 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2008 | 438 | 0.110 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 306 | 0.110 |
Why?
|
| Fluoroscopy | 1 | 2013 | 152 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 201 | 0.110 |
Why?
|
| Reoperation | 3 | 2013 | 467 | 0.110 |
Why?
|
| South Carolina | 4 | 2013 | 2750 | 0.110 |
Why?
|
| Sex Distribution | 2 | 2010 | 272 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 235 | 0.100 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2013 | 101 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1085 | 0.100 |
Why?
|
| Interprofessional Relations | 1 | 2013 | 188 | 0.100 |
Why?
|
| Alberta | 3 | 2008 | 15 | 0.100 |
Why?
|
| Genotype | 3 | 2020 | 785 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2012 | 220 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2013 | 113 | 0.100 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 214 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2014 | 1737 | 0.100 |
Why?
|
| Palliative Care | 1 | 2014 | 271 | 0.100 |
Why?
|
| Sterilization | 1 | 2011 | 29 | 0.100 |
Why?
|
| Hydromorphone | 1 | 2011 | 14 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 737 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 782 | 0.100 |
Why?
|
| Dilatation, Pathologic | 1 | 2011 | 58 | 0.100 |
Why?
|
| Somatosensory Cortex | 1 | 2011 | 22 | 0.100 |
Why?
|
| Swine | 2 | 2010 | 672 | 0.100 |
Why?
|
| Lymphatic Diseases | 1 | 2011 | 27 | 0.100 |
Why?
|
| Octreotide | 1 | 2010 | 21 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2021 | 1506 | 0.100 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2010 | 14 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 467 | 0.100 |
Why?
|
| Anxiety | 1 | 2014 | 422 | 0.090 |
Why?
|
| Hospitalization | 2 | 2013 | 977 | 0.090 |
Why?
|
| Gastrectomy | 1 | 2010 | 24 | 0.090 |
Why?
|
| Lithotripsy | 1 | 2010 | 18 | 0.090 |
Why?
|
| Mental Health | 1 | 2013 | 278 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 785 | 0.090 |
Why?
|
| Gastrointestinal Agents | 1 | 2010 | 51 | 0.090 |
Why?
|
| Cystic Fibrosis | 1 | 2014 | 283 | 0.090 |
Why?
|
| Disinfection | 1 | 2011 | 112 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 78 | 0.090 |
Why?
|
| Enterococcus | 1 | 2010 | 29 | 0.090 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 121 | 0.090 |
Why?
|
| Ultrasonography | 2 | 2014 | 453 | 0.090 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2010 | 35 | 0.090 |
Why?
|
| Vitamins | 1 | 2010 | 134 | 0.090 |
Why?
|
| Insulin | 1 | 2013 | 617 | 0.090 |
Why?
|
| Streptococcal Infections | 1 | 2010 | 53 | 0.090 |
Why?
|
| Liver Neoplasms | 2 | 2011 | 334 | 0.090 |
Why?
|
| Equipment Design | 2 | 2009 | 500 | 0.090 |
Why?
|
| Electric Stimulation Therapy | 1 | 2011 | 147 | 0.090 |
Why?
|
| Algorithms | 2 | 2015 | 1194 | 0.090 |
Why?
|
| Lipids | 1 | 2011 | 298 | 0.090 |
Why?
|
| Disease Progression | 2 | 2019 | 1037 | 0.090 |
Why?
|
| Enbucrilate | 1 | 2008 | 5 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2010 | 258 | 0.080 |
Why?
|
| Intestinal Perforation | 1 | 2008 | 35 | 0.080 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 103 | 0.080 |
Why?
|
| Patient Selection | 2 | 2013 | 592 | 0.080 |
Why?
|
| Digestive System Abnormalities | 1 | 2008 | 7 | 0.080 |
Why?
|
| Child | 4 | 2020 | 6400 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2011 | 631 | 0.080 |
Why?
|
| Sigmoidoscopy | 1 | 2008 | 38 | 0.080 |
Why?
|
| Premedication | 1 | 2008 | 49 | 0.080 |
Why?
|
| Analgesics | 1 | 2009 | 118 | 0.080 |
Why?
|
| Wound Healing | 1 | 2010 | 260 | 0.080 |
Why?
|
| Constriction, Pathologic | 3 | 2016 | 236 | 0.080 |
Why?
|
| CA-19-9 Antigen | 1 | 2007 | 5 | 0.080 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2007 | 17 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 122 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 107 | 0.080 |
Why?
|
| Single-Blind Method | 1 | 2008 | 249 | 0.080 |
Why?
|
| Patient Care Team | 2 | 2010 | 311 | 0.070 |
Why?
|
| Surgical Stomas | 1 | 2006 | 3 | 0.070 |
Why?
|
| Peptic Ulcer | 1 | 2006 | 37 | 0.070 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2006 | 20 | 0.070 |
Why?
|
| Depression | 1 | 2014 | 942 | 0.070 |
Why?
|
| Equipment Safety | 1 | 2006 | 50 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 546 | 0.070 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2005 | 23 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 240 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 215 | 0.070 |
Why?
|
| Interdepartmental Relations | 1 | 2005 | 1 | 0.070 |
Why?
|
| Melena | 1 | 2005 | 8 | 0.070 |
Why?
|
| Forms and Records Control | 1 | 2005 | 16 | 0.070 |
Why?
|
| Hematemesis | 1 | 2005 | 14 | 0.070 |
Why?
|
| Fibrosis | 1 | 2007 | 371 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 191 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2005 | 114 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2005 | 169 | 0.060 |
Why?
|
| Polymethyl Methacrylate | 1 | 2004 | 31 | 0.060 |
Why?
|
| Polyvinyls | 1 | 2004 | 24 | 0.060 |
Why?
|
| Esophagectomy | 1 | 2004 | 26 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2004 | 24 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 791 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2009 | 439 | 0.060 |
Why?
|
| Patient Admission | 1 | 2004 | 99 | 0.060 |
Why?
|
| Biomarkers | 2 | 2011 | 1593 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 193 | 0.060 |
Why?
|
| Bile Duct Neoplasms | 1 | 2003 | 39 | 0.060 |
Why?
|
| Animals | 3 | 2010 | 20877 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1548 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2005 | 1039 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1174 | 0.060 |
Why?
|
| Comorbidity | 2 | 2019 | 1425 | 0.050 |
Why?
|
| Bile Duct Diseases | 1 | 2002 | 28 | 0.050 |
Why?
|
| Intestinal Diseases | 1 | 2002 | 25 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2006 | 3185 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2007 | 1329 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2004 | 229 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2002 | 124 | 0.050 |
Why?
|
| Markov Chains | 1 | 2002 | 133 | 0.050 |
Why?
|
| Helicobacter pylori | 1 | 2002 | 54 | 0.050 |
Why?
|
| Vitamin B 12 | 1 | 2001 | 21 | 0.050 |
Why?
|
| Homocysteine | 1 | 2001 | 26 | 0.050 |
Why?
|
| Prosthesis Implantation | 2 | 2016 | 83 | 0.050 |
Why?
|
| Linear Models | 2 | 2013 | 521 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 1172 | 0.050 |
Why?
|
| Polyethylene | 1 | 2001 | 31 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 951 | 0.050 |
Why?
|
| Endocarditis | 1 | 2000 | 14 | 0.050 |
Why?
|
| Amphotericin B | 1 | 2000 | 26 | 0.050 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2020 | 10 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2000 | 55 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2001 | 155 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2000 | 164 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2002 | 193 | 0.050 |
Why?
|
| Age of Onset | 1 | 2020 | 188 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2000 | 108 | 0.040 |
Why?
|
| Steroids | 1 | 2000 | 84 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2014 | 239 | 0.040 |
Why?
|
| Mutation | 2 | 2014 | 1213 | 0.040 |
Why?
|
| Consensus | 2 | 2009 | 211 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 90 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 370 | 0.040 |
Why?
|
| Atrophy | 1 | 2016 | 112 | 0.040 |
Why?
|
| Tissue Banks | 1 | 2016 | 13 | 0.040 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2016 | 14 | 0.040 |
Why?
|
| Efficiency | 1 | 2016 | 49 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 109 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 79 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 955 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 201 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 83 | 0.030 |
Why?
|
| Neoplasms | 1 | 2007 | 1660 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1054 | 0.030 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2015 | 15 | 0.030 |
Why?
|
| Gastroenterostomy | 1 | 2015 | 8 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 172 | 0.030 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2015 | 34 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 57 | 0.030 |
Why?
|
| Publishing | 1 | 2016 | 89 | 0.030 |
Why?
|
| Dilatation | 1 | 2015 | 58 | 0.030 |
Why?
|
| Pressure | 1 | 2015 | 252 | 0.030 |
Why?
|
| Chlorides | 1 | 2014 | 68 | 0.030 |
Why?
|
| Capecitabine | 1 | 2014 | 11 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 57 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 21 | 0.030 |
Why?
|
| Reproduction | 1 | 2014 | 48 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2015 | 110 | 0.030 |
Why?
|
| Narcotics | 1 | 2014 | 65 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 125 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 83 | 0.030 |
Why?
|
| Diagnosis-Related Groups | 1 | 2013 | 28 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 130 | 0.030 |
Why?
|
| Psychometrics | 1 | 2016 | 514 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 107 | 0.030 |
Why?
|
| Pancreaticojejunostomy | 1 | 2013 | 21 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 326 | 0.030 |
Why?
|
| Pain, Intractable | 1 | 2013 | 28 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 84 | 0.030 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2013 | 49 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 145 | 0.030 |
Why?
|
| Voluntary Programs | 1 | 2012 | 9 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 567 | 0.030 |
Why?
|
| Homozygote | 1 | 2012 | 119 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2012 | 207 | 0.030 |
Why?
|
| Telephone | 1 | 2013 | 160 | 0.030 |
Why?
|
| Family Health | 1 | 2012 | 83 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 281 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2013 | 204 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 946 | 0.020 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2010 | 7 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 563 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2013 | 267 | 0.020 |
Why?
|
| United Kingdom | 1 | 2011 | 152 | 0.020 |
Why?
|
| Autonomic Nerve Block | 1 | 2010 | 15 | 0.020 |
Why?
|
| Electrodes | 1 | 2011 | 147 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 59 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 502 | 0.020 |
Why?
|
| Mediastinum | 1 | 2010 | 39 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 186 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2010 | 119 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2010 | 85 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 274 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2011 | 275 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2008 | 25 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2010 | 291 | 0.020 |
Why?
|
| Secretin | 1 | 2008 | 18 | 0.020 |
Why?
|
| Stomach | 1 | 2008 | 80 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 446 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2008 | 63 | 0.020 |
Why?
|
| Gastroscopy | 1 | 2008 | 45 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 85 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 799 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 306 | 0.020 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2007 | 3 | 0.020 |
Why?
|
| Urban Population | 1 | 2008 | 254 | 0.020 |
Why?
|
| H(+)-K(+)-Exchanging ATPase | 1 | 2006 | 45 | 0.020 |
Why?
|
| Probability | 1 | 2004 | 244 | 0.020 |
Why?
|
| Age Distribution | 1 | 2004 | 319 | 0.010 |
Why?
|
| Registries | 1 | 2004 | 730 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2001 | 112 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2001 | 714 | 0.010 |
Why?
|